PET Image in PAH Patients

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

July 11, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Pulmonary Arterial Hypertension
Interventions
DIAGNOSTIC_TEST

18F-FGLN PET Imaging

PET/CT Imaging: The study visit will take around 3-4 hours, the duration of PET will be around 90 minutes. Women should have negative pregnancy test prior to the study. An intravenous catheter will be placed in the subject's opposite arm, which will be used for radiotracer administration. A low-dose helical CT scan will be performed during a \~15 sec inspiratory breath hold and used for CT-based attenuation correction of PET emission data and as an anatomical reference for image analyses. Participants will be retained in the PET facility following the PET scan to promote urination to increase elimination of the radiotracer.

DRUG

(18F)FPGLU

\[F-18\]FGln is a natural glutamine derivative was synthesized to explore its potential application of imaging glutamine uptake for cancer diagnosis. The proposed research study will provide preliminary evidence of the potential to utilize \[F-18\]FGln as a non-invasive imaging biomarker of glutamine flux and metabolism across a range of PAH subjects.

Trial Locations (1)

15213

RECRUITING

Montefiore Hospital Clinical and Translational Research Center, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Stephen Y. Chan

OTHER